Table 2 Primary and secondary endpoints at 12 weeks after treatment initiation

From: The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Continuous secondary endpoints

Dapagliflozin (n = 162)

Placebo (n = 162)

Effect size

P value

KCCQ-CS, meana

68.6 (66.2, 71.0)

62.8 (60.4, 65.3)

5.8 (2.3, 9.2)

0.001

KCCQ-OS, meana

68.9 (66.5, 71.3)

64.5 (62.1, 66.8)

4.5 (1.1, 7.8)

0.009

6MWT, mean, ma

262 (252, 272)

242 (232, 252)

20.1 (5.6, 34.7)

0.007

NTproBNP, mean, pg ml–1a

733 (673, 799)

739 (678, 805)

0.99 (0.88, 1.12)b

0.900

BNP, mean, pg ml–1a

147 (136, 160)

147 (136, 160)

1.00 (0.89, 1.12)b

0.990

Systolic blood pressure, mean, mmHga

133 (130, 135)

133 (131, 136)

−0.6 (−4.4, 3.3)

0.780

Weight, mean, kga

101.3 (100.9, 101.8)

102.1 (101.6, 102.6)

−0.72 (−1.42, −0.01)

0.046

  1. Values are shown as adjusted means (95% CI) for continuous variables.
  2. aAdjusted for the corresponding baseline value, history of T2D, sex, AF, baseline eGFR and LVEF.
  3. bRatio of dapagliflozin compared to placebo.
Back to article page